Influenza Vaccination After Acute Coronary Syndrome

Last updated: January 10, 2026
Sponsor: Tongji Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chest Pain

Myocardial Ischemia

Cardiac Disease

Treatment

Placebo

Influenza vaccine

Clinical Study ID

NCT07259252
InVaACS
  • Ages 18-80
  • All Genders

Study Summary

The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are:

  • Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke?

  • Whether influenza vaccination can decrease events of all cause death, unplanned revascularization, unplanned hospitalization for heart failure or for arrhythmia, stent thrombosis?

If there is a comparison group: Researchers will compare influenza vaccination and placebo to see if adverse cardiac events decrease.

Participants will receive an influenza vaccination or placebo after enrollment and phone calls for follow-up at 1 month, 3 months, 6 months and 1 year after discharge.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. ACS patient aged from 18 to 80 years.

  2. Volunteer for the study and written informed consent.

Exclusion

Exclusion Criteria:

  1. Participate in any drug clinical trials within 3 months.

  2. Patients with life-threatening complications, or the researchers determined that thesurvival time of patients with no more than 1 years.

  3. Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressivelower limbs or deaf patients).

  4. Previous history of cancer or tumor, or pathological examination confirmedprecancerous lesions (such as breast ductal carcinoma in situ, or atypicalhyperplasia of the cervix).

  5. Patients refused to comply with the requirements of this study to complete theresearch work.

  6. Patients Received influenza vaccination within 1 year.

  7. Patients with contraindications for influenza vaccination.

Study Design

Total Participants: 6620
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
December 03, 2025
Estimated Completion Date:
March 30, 2029

Connect with a study center

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan 1791247, Hubei 1806949 430030
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.